Daratumumab is a human IgG1kappa monoclonal antibody that specifically binds to the CD38 glycoprotein, which is highly expressed on malignant plasma cells in multiple myeloma. It is widely used in both in vitro and in vivo research to study mechanisms of antibody-dependent cellular cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC) against myeloma cells.
Concentration:
22 mg/mL
Molecular Weight:
Approximately 148kDa
Purity:
98.60% (May vary between batches)
CAS Number:
[945721-28-8]
Target:
ADC Antibody,CD38
* VAT and and shipping costs not included. Errors and price changes excepted